Live
FierceBiotechAfter Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's Redwood City outpostFDA News ReleasesFDA Expands Market Access, Authorizes New ENDS ProductsEndpoints NewsIntercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharmaClinical OMICsMuscle Quality and Fat Distribution Predict Mortality Risk Better than BMIEndpoints NewsPfizer's Albert Bourla says he has no mega-merger plansClinical OMICsGenotype-Guided Antidepressants Could Have Long-Term BenefitsModernaBoston biotech firms back new effort to preserve U.S. edge in life sciences - The Business JournalsRevvityRevvity Outperforms in Q1 2026 Driven by Pharma Rebound and Strategic Portfolio Shifts - Lab ManagerEndpoints NewsBioNTech to scale down manufacturing, over 1,800 jobs on the lineEndpoints NewsParsley Health goes in-network nationwideRevvityWhy Is Revvity (RVTY) Stock Rocketing Higher Today - TradingViewPfizerPfizer beats estimates but investors cautious - The Pharma Letter
PharmaVoice Jan 21, 2026

Cancer R&D is thriving. Here are the areas to watch in 2026.

Cancer R&D is thriving. Here are the areas to watch in 2026.

Original
Body unavailable. Use the original source.